Tolazamide-induced cholestasis

Area of Science:

• Pharmacology
• Hepatology
• Endocrinology

Background:

• Sulfonylurea drugs are commonly used to manage type 2 diabetes.
• Tolazamide was previously considered a rare cause of jaundice with no cross-sensitivity.
• Chlorpropamide is another sulfonylurea agent used for diabetes treatment.

Observation:

• A patient developed self-limited cholestatic jaundice after chlorpropamide treatment.
• The same patient later experienced recurrent jaundice upon treatment with tolazamide.
• Jaundice resolved after discontinuing tolazamide therapy.

Findings:

• The case suggests tolazamide can cause cholestatic jaundice.
• Evidence indicates potential hepatic cross-sensitivity between tolazamide and chlorpropamide.
• This contradicts the established understanding of sulfonylurea drug reactions.

Implications:

• Clinicians should be aware of potential liver toxicity with tolazamide.
• Further investigation into sulfonylurea-induced liver injury is warranted.
• This finding may impact prescribing practices for diabetic patients with liver concerns.